A study from Ethiopia followed PCR-confirmed COVID-19 patients for a median time of 31 days used lateral flow immunoassays to quantify anti-spike and anti-nucleoprotein IgM, IgG, and an electro-chemiluminescent assay to quantify total anti-nucleoprotein immunoglobulins. The gene discussed is CD40LG; the disease is COVID-19.